ACT Capital Partners, L.P.’s Palisade Bio PALI Stock Holding History

ACT Capital Partners, L.P.’s Portfolio PALI Stock Details PALI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$415K	Buy	+307,500	New	+$600K	0.27%	38

Other funds holding PALI

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return

ACT Capital Partners, L.P.'s PALI Position: Q3 2026 in Review

ACT Capital Partners, L.P. opened a new position in Palisade Bio (PALI) in Q3 2026: 307,500 shares worth $415K. The stake represents 0.27% of the portfolio and ranks #38 among its holdings.

26 funds tracked by Wall St. Rank hold PALI as of Q3 2026.

ACT Capital Partners, L.P. held 307,500 shares of Palisade Bio worth $415K as of Q3 2026.
Palisade Bio was a new ACT Capital Partners, L.P. position in Q3 2026.
Palisade Bio made up 0.27% of ACT Capital Partners, L.P.'s portfolio in Q3 2026, its #38 holding.
26 funds tracked by Wall St. Rank held Palisade Bio as of Q3 2026.

Based on ACT Capital Partners, L.P.'s 13F filing for Q3 2026, filed 6 Nov 2026.